Antimicrobial resistance in Clostridium difficile

被引:134
作者
Huang, Haihui [1 ,2 ]
Weintraub, Andrej [2 ]
Fang, Hong [2 ]
Nord, Carl Erik [2 ]
机构
[1] Fudan Univ, Inst Antibiot, Huashan Hosp, Shanghai 200040, Peoples R China
[2] Karolinska Univ Hosp, Karolinska Inst, Div Clin Microbiol, Dept Lab Med, SE-14186 Huddinge, Sweden
关键词
Clostridium difficile; Antimicrobial susceptibility; Resistance mechanisms; B MLSB RESISTANCE; METRONIDAZOLE RESISTANCE; REDUCED SUSCEPTIBILITY; ANTIBIOTIC-RESISTANCE; QUINOLONE RESISTANCE; PCR RIBOTYPES; FUSIDIC ACID; NIM GENES; MOXIFLOXACIN; MACROLIDE;
D O I
10.1016/j.ijantimicag.2009.09.012
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Clostridium difficile is the leading cause of hospital-acquired diarrhoea and the number of outbreaks has risen markedly since 2003. The emergence and spread of resistance in C. difficile is complicating treatment and prevention. Most isolates are still susceptible to vancomycin and metronidazole (MTZ), however transient and heteroresistance to MTZ have been reported. The prevalence of resistance to other antimicrobial agents is highly variable in different populations and in different countries, ranging from 0% to 100%. Isolates of common polymerase chain reaction (PCR) ribotypes are more resistant than uncommonribotypes. Most of the resistance mechanisms that have been identified in C. difficile are similar to those in other Gram-positive bacteria, including mutation, selection and acquisition of the genetic information that encodes resistance. Better antibiotic stewardship and infection control are needed to prevent further spread of resistance in C. difficile. (C) 2009 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:516 / 522
页数:7
相关论文
共 70 条
[1]   Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA [J].
Ackermann, G ;
Tang, YJ ;
Kueper, R ;
Heisig, P ;
Rodloff, AC ;
Silva, J ;
Cohen, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (08) :2348-2353
[2]   Prevalence and association of macrolide-lincosamide- streptogramin B (MLSB) resistance with resistance to moxifloxacin in Clostridium difficile [J].
Ackermann, G ;
Degner, A ;
Cohen, SH ;
Silva, J ;
Rodloff, AC .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (03) :599-603
[3]   Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish University Hospital [J].
Aspevall, O ;
Lundberg, A ;
Burman, LG ;
Åkerlund, T ;
Svenungsson, B .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (05) :1890-1892
[4]  
BACCI S, 2009, EURO SURVEILL, V14
[5]   Emergence of reduced susceptibility to metronidazole in Clostridium difficile [J].
Baines, Simon D. ;
O'Connor, Rachael ;
Freeman, Jane ;
Fawley, Warren N. ;
Harmanus, Celine ;
Mastrantonio, Paola ;
Kuijper, Ed J. ;
Wilcox, Mark H. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (05) :1046-1052
[6]   Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates [J].
Barbut, F. ;
Mastrantonio, P. ;
Delmee, M. ;
Brazier, J. ;
Kuijper, E. ;
Poxton, I. .
CLINICAL MICROBIOLOGY AND INFECTION, 2007, 13 (11) :1048-1057
[7]   ANTIBIOTIC-ASSOCIATED PSEUDOMEMBRANOUS COLITIS DUE TO TOXIN-PRODUCING CLOSTRIDIA [J].
BARTLETT, JG ;
CHANG, TW ;
GURWITH, M ;
GORBACH, SL ;
ONDERDONK, AB .
NEW ENGLAND JOURNAL OF MEDICINE, 1978, 298 (10) :531-534
[8]   New antimicrobial agents for patients with Clostridium difficile infections [J].
Bartlett J.G. .
Current Infectious Disease Reports, 2009, 11 (1) :21-28
[9]   FECAL METRONIDAZOLE CONCENTRATIONS DURING ORAL AND INTRAVENOUS THERAPY FOR ANTIBIOTIC ASSOCIATED COLITIS DUE TO CLOSTRIDIUM-DIFFICILE [J].
BOLTON, RP ;
CULSHAW, MA .
GUT, 1986, 27 (10) :1169-1172
[10]   In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in southern Quebec, Canada [J].
Bourgault, Anne-Marie ;
Lamothe, Francois ;
Loo, Vivian G. ;
Poirier, Louise .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (10) :3473-3475